RecruitingNCT07095465
Long-term ACP-204 treatment for psychosis in Lewy body dementia
About this title
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
Read the official source — NCT07095465Medication studyAges 55–84Multiple countriesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 55 years to 84 years.
- Listed locations
- Irvine and 31 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 14, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 126
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Bulgaria, ...
- Age range
- From 55 Years to 84 Years
- Official registry ID
- NCT07095465
- Official title
Show the full official title
52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
Recruitment & locations
RecruitingIrvine, United States · Aventura, United States · Boca Raton, United States
26 more locations
- Lady Lake, United States
- Miami, United States
- West Palm Beach, United States
- Honolulu, United States
- Kansas City, United States
- Commack, United States
- Columbus, United States
- Tulsa, United States
- Cypress, United States
- San Antonio, United States
- Stafford, United States
- Richmond, United States
- Kirkland, United States
- Cherven Bryag, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Brno, Czechia
- Choceň, Czechia
- Rychnov nad Kněžnou, Czechia
- Tours, France
- Bron, France
- Strasbourg, France
- Naples, Italy
- Roma, Italy
- Belgrade, Serbia
- Czechia
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Does this study involve medication?
Yes. The study involves medication, including ACP-204.
Who can participate?
Listed age limits: 55 years to 84 years.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to explore more studies?
Explore studiesRelated studies
Long-term safety of LB-102 in adults with schizophrenia
A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....